PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :		(11) International Publication Number: WO 96/30523
C12N 15/49, 15/62, C07K 14/16, 19/00, 14/03, A61K 39/21, 39/245	A3	(43) International Publication Date: 3 October 1996 (03.10.96)
(21) International Application Number: PCT/EP	96/014	(74) Agent: VOSSIUS & PARTNER; P.O. Box 86 07 67, D-81634 München (DE).
95 10 4849.5 31 March 1995 (31.03.95) (34) Countries for which the regional or international application was filed: 95 10 4850.3 31 March 1995 (31.03.95) (34) Countries for which the regional or international application was filed: (71)(72) Applicant and Inventor: WOLF, Hans [DE/DI] Jägerhuber-Strasse 9, D-82319 Stamberg (DE). (72) Inventors; and (75) Inventors/Applicants (for US only): WAGNER, Ra	DE et DE et DE et [-/Det]	(81) Designated States: BR, CA, CN, JP, US, ARIPO patent (KE, LS, MW, SD, SZ, UG), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments. (88) Date of publication of the international search report: 17 April 1997 (17.04.97)
DEMIL, Ludwig [-/DE]; Schneitweger Strasse 93128 Regensburg (DE). OSTERRIEDER, Klau Holzhauser Strasse 30, D-86919 Utting (DE). Frank [-/DE]; Gebhardstrasse 5, D-93059 R (DE).	NOTI egensb	E.J; A., urg

(54) Title: ANTIGEN PRESENTATION SYSTEM BASED ON RETROVIRUS-LIKE PARTICLES

(57) Abstract

The present invention relates to the provision of an antigen presentation system on the basis of a DNA sequence encoding a protein capable of self assembly into particles without a lipid membrane, preferably a retroviral group-specific antigen (gag) that can be used, e.g., for the preventive and therapeutic immunization of mammals against infectious diseases or neoplasias.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
ΑŪ	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgystan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic	SD	Sudan
CF	Central African Republic		of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SG	Singapore
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LR	Liberia	SZ	Swaziland
CS	Czechoslovakia	LT	Lithuania	TD	Chad
CZ	Czech Republic	LU	Luxembourg	TG	Togo
DE	Germany	LV	Larvia	TJ	Tajikistan
DK	Denmark	MC	Monaco	TT	Trinidad and Tobago
EE	Estonia	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	UG	Uganda
FI	Finland	ML	Mali	US	United States of America
FR	France	MN	Mongolia	UZ	Uzbekistan
GA	Gabon	MR	Mauritania	VN	Viet Nam

Inter onal Application No PC1/EP 96/01433

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C12N15/49 C12N15/62 C07K14/03 C07K19/00 C07K14/16 A61K39/245 A61K39/21

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 6 C12N A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 91 07425 A (ONCOGEN LIMITED PARTNERSHIP) 30 May 1991	1-9, 11-13, 16,17, 19-26
	see examples 8,9	
X	EP 0 508 809 A (BRITISH BIOTECHNOLOGY LIMITED) 14 October 1992 see the whole document	1-26
X	WO 91 05864 A (CONNAUGHT LABORATORIES LIMITED) 2 May 1991	1,3,6-9, 11-13, 16,19-26
	see the whole document	
	-/	

* Special categories of cited documents: A' document defining the general state of the art which is not considered to be of particular relevance	"I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 'E' earlier document but published on or after the international filing date 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) 'O' document referring to an oral disclosure, use, exhibition or other means 'P' document published prior to the international filing date but later than the priority date claimed 	 'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. '&' document member of the same patent family
Date of the actual completion of the international search 6 March 1997	Date of mailing of the international search report 17.03.97
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo ul, Fax (+31-70) 340-3016	Authorized officer Skelly, J

2

Interr vial Application No PC1/EP 96/01433

Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
WO 91 19803 A (APPLIED BIOTECHNOLOGY) 26 December 1991	1,3,6-9, 11-13, 16,19-21
see the whole document	
WO 92 03537 A (THERION BIOLOGICS CORPORATION) 5 March 1992	1,3-8, 15-17, 19-26
see the whole document	
CA 2 098 029 A (CONNAUGHT LABORATORIES) 10 December 1994	1-3, 6-13,16, 17,19-26
	6.0
J. GEN. VIROL., vol. 75, 1994, pages 2041-2046, XP002027076 N. OSTERRIEDER ET AL.: "Expression of equine herpesvirus type 1 glycoprotein in E. coli and insect cells" see the whole document	6-8
GENE, vol. 58, 1987, pages 149-154, XP002027077 M. MOTZ ET AL.: "Truncated versions of two major Epstein-Barr viral glycoproteins are secreted by recombinant chinese hamster ovary cells" see page 151 - page 152, column 2, line 3	15
J. VIROL., vol. 64, no. 6, 1990, pages 2653-2659, XP002027078 O. HAFFAR ET AL.: "Human immunodeficiency virus-like, non-replicating gag-env particles assemble in a recombinant vaccinia virus expression system" see the whole document	1
VIROLOGY, vol. 208, 1995, pages 500-510, XP002027079 N. OSTERRIEDER ET AL.: "Protection against EHV1 challenge infection in the murine model after vaccination with various formulations of recombinant glycoprotein gp14 (gB)" see the whole document -/	1-26
	December 1991 see the whole document W0 92 03537 A (THERION BIOLOGICS CORPORATION) 5 March 1992 see the whole document CA 2 098 029 A (CONNAUGHT LABORATORIES) 10 December 1994 see the whole document J. GEN. VIROL., vol. 75, 1994, pages 2041-2046, XP002027076 N. OSTERRIEDER ET AL.: "Expression of equine herpesvirus type 1 glycoprotein in E. coli and insect cells" see the whole document GENE, vol. 58, 1987, pages 149-154, XP002027077 M. MOTZ ET AL.: "Truncated versions of two major Epstein-Barr viral glycoproteins are secreted by recombinant chinese hamster ovary cells" see page 151 - page 152, column 2, line 3 J. VIROL., vol. 64, no. 6, 1990, pages 2653-2659, XP002027078 O. HAFFAR ET AL.: "Human immunodeficiency virus-like, non-replicating gag-env particles assemble in a recombinant vaccinia virus expression system" see the whole document VIROLOGY, vol. 208, 1995, pages 500-510, XP002027079 N. OSTERRIEDER ET AL.: "Protection against EHV1 challenge infection in the murine model after vaccination with various formulations of recombinant glycoprotein gp14 (gB)" see the whole document

Inter Conal Application No
PCI/EP 96/01433

		PC:/EP 96/01433
(Continue)	on) D CUMENTS CONSIDERED TO BE RELEVANT	
ategory *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
>,х	WO 96 05292 A (CONNAUGHT LABORATORIES LIMITED) 22 February 1996	1-3, 6-13, 15-17, 19-26
	see examples 1-5	
		1
		1
		l
		}

International application No.

PCT/EP 96/01433

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)	
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:	
1. X Claims Nos.: 26 because they relate to subject matter not required to be searched by this Authority, namely: Remark: Although claim 26 is directed to a method of treatment of (diagnostic method practised on) the human/animal body, the search has been carried out and based on the alleged effects of the	
compound/composition. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:	
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).	
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)	_
This International Searching Authority found multiple inventions in this international application, as follows:	
1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.	
2. As all searchable claims could be searches without effort justifying an additional fee, this Authority did not invite payment of any additional fee.	
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:	
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:	
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.	

nformation on patent family members

Inter 'onal Application No PCI/EP 96/01433

		ן רי	1/EP 90/01433
Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9107425 A	30-05-91	AU 636944 B AU 6905591 A CA 2068713 A CN 1054613 A CN 1054793 A EP 0502105 A ES 2052478 T JP 5503629 T OA 9698 A	25-09-91 09-09-92 16-07-94 17-06-93
EP 508809 A	14-10-92	AU 1538692 A CA 2107879 A WO 9218621 A JP 6506826 T NO 933613 A ZA 9202659 A	11-10-92 29-10-92 04-08-94 09-12-93
WO 9105864 A	02-05-91	CA 2067333 A EP 0495811 A JP 2537570 E JP 4506301 T US 5571712 A US 5439809 A	29-07-92 25-09-96 05-11-92 05-11-96
WO 9119803 A	26-12-91	NONE	
WO 9203537 A	05-03-92	CA 2089497 (EP 0652967 (JP 6500232 US 5420026 (A 17-05-95 T 13-01-94
CA 2098029 A	10-12-94	NONE	
WO 9605292 A	22-02-96	AU 3159995	A 07-03-96